Experts agreed that the biggest threat to progress on overdose deaths is the looming Medicaid cuts. Researchers at Penn’s ...

A startup tackling the 'dumb problems' at the intersection of AI and bio, accuracy of AI scribes, and more.

UniQure has submitted its Huntington’s gene therapy to the FDA, investors remain unenthusiastic on Novo Nordisk, and more of ...

At a "practice of last resort," pediatricians prioritize allaying parents' vaccine concerns without hardline dismissals.

Analysts say private deals involve drugmakers agreeing to lower prices in Medicaid, where prices are low, in return for no ...

The whole of my field has been flattened into a single lazy question: Did the health care system fail her?” writes Jennifer ...

Ultragenyx said its experimental therapy for Angelman syndrome, a rare disease, showed no benefit compared to a sham treatment in a Phase 3 trial.

UniQure submitted applications to the FDA and the UK’s MHRA, seeking the marketing approval of AMT-130, its treatment for ...

The federal spending bill has an important provision for researchers, and Trump announced more MFN deals with pharma firms.

Novartis and Bristol Myers Squibb have paused multiple cell therapy trials, while $480,000 has now become a routine price for ...

The next DSM and the algorithm, an unexpected discovery on alpha-gal syndrome, and more health news from Morning Rounds ...

Shihipar directs narrative projects and policy impact initiatives at the People, Place, and Health Collective at the Brown ...